Disclosure Of Entity's Operating Segments [Text Block]

OSE Immunotherapeutics - Filing #2816794

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
Disclosure of entity's operating segments [text block]
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
26 306 EUR
10 432 EUR
Tax expense (income)
364,000 EUR
2 692 EUR
Profit (loss) before tax
17 213 EUR
19 246 EUR
Profit (loss)
16 850 EUR
16 850 EUR
16 555 EUR
16 555 EUR
Assets
101 876 EUR
96 973 EUR
Cash flows from (used in) operating activities
9 919 EUR
19 550 EUR
Cash flows from (used in) investing activities
827,000 EUR
504,000 EUR
Cash flows from (used in) financing activities
14 957 EUR
23 580 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.